In neurology, the precise measurement of biomarkers across the ATNI framework – Amyloid (A), Tau (T), and Neurodegeneration (N) and Inflammation (I) – is critical to enabling earlier detection, resolution of disease heterogeneity, and better prediction of therapeutic outcomes in Alzheimer’s Disease.
The NULISAqpcr Assays offer single- and low-plex solutions to reliably quantify, with attomolar sensitivity, low‑abundance biomarkers across pathways and processes that are most relevant in CNS disease, including important tau isoforms.
A single-plex solution setting a new benchmark for absolute quantitation of the phosphorylated tau 217 (pTau217) isoform originating specifically from the central nervous system.
Providing absolute quantitation of established Alzheimer’s Disease biomarkers – including APOE4, BD-pTau217, Aβ42, GFAP, and NfL – in a single multiplexed assay.
This Nature Communications paper demonstrates the exceptional performance of the NUcleic acid Linked Immuno-Sandwich Assay (NULISA™) in detecting biologically important low-abundance biomarkers.
As both a Certified Service Provider for NULISA panels and the only multi-omics partner with a molecular-clinical database in which to confirm findings from these assays, Sapient uniquely offers:
"*" indicates required fields
